Renoprotective effect of renal liver-type fatty acid binding protein and angiotensin II type 1a receptor loss in renal injury caused by RAS activation

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 6, 2014, Pages

  Ichikawa, Daisuke ^a   Kamijo Ikemori, Atsuko ^a   Sugaya, Takeshi ^a   Shibagaki, Yugo ^a   Yasuda, Takashi ^a   Katayama, Kimie ^a   Hoshino, Seiko ^a   Igarashi Migitaka, Junko ^a   Hirata, Kazuaki ^a   Kimura, Kenjiro ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

L FABP; Oxidative stress; RAS activation; Tubulointerstitial damage

Indexed keywords

ANGIOTENSIN 1A RECEPTOR; FATTY ACID BINDING PROTEIN; LIVER TYPE FATTY ACID BINDING PROTEIN; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE INACTIVATION; HYPERTENSION; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ANIMAL; AT1A KNOCKOUT; BIOSYNTHESIS; CHRONIC KIDNEY FAILURE; HUMAN; KNOCKOUT MOUSE; L-FABP; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; RAS ACTIVATION; SALT INTAKE; TRANSGENIC MOUSE; TUBULOINTERSTITIAL DAMAGE;

AT1A KNOCKOUT; L-FABP; OXIDATIVE STRESS; RAS ACTIVATION; TUBULOINTERSTITIAL DAMAGE;

ANIMALS; FATTY ACID-BINDING PROTEINS; HUMANS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL INSUFFICIENCY, CHRONIC; RENIN-ANGIOTENSIN SYSTEM; SODIUM CHLORIDE, DIETARY;

EID: 84900297659     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00460.2013     Document Type: Article

References (33)

1. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366: 2026-2033, 2005.
2. de Leeuw PW. ACP Journal Club. Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs. Ann Intern Med 158: JC7, 2013.
3. Harrison-Bernard LM, Navar LG, Ho MM, Vinson GP, el-Dahr SS. Immunohistochemical localization of ANG II AT1 receptor in adult rat kidney using a monoclonal antibody. Am J Physiol Renal Physiol 273: F170-F177, 1997.
4. Hisada Y, Sugaya T, Tanaka S, Suzuki Y, Ra C, Kimura K, Fukamizu A. An essential role of angiotensin II receptor type 1a in recipient kidney, not in transplanted peripheral blood leukocytes, in progressive immunemediated renal injury. Lab Invest 81: 1243-1251, 2001.
5. Hisada Y, Sugaya T, Yamanouchi M, Uchida H, Fujimura H, Sakurai H, Fukamizu A, Murakami K. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 103: 627-635, 1999.
6. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354: 131-140, 2006.
7. Ichikawa D, Kamijo-Ikemori A, Sugaya T, Yasuda T, Hoshino S, Igarashi-Migitaka J, Hirata K, Kimura K. Renal liver-type fatty acid binding protein attenuates angiotensin II-induced renal injury. Hypertension 60: 973-980, 2012.
8. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, Honda A, Okabe M, Fujino T, Hirata Y, Omata M, Kaneko R, Fujii H, Fukamizu A, Kimura K. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 165: 1243-1255, 2004.
9. Kamijo-Ikemori A, Sugaya T, Obama A, Hiroi J, Miura H, Watanabe M, Kumai T, Ohtani-Kaneko R, Hirata K, Kimura K. Liver-type fatty acid-binding protein attenuates renal injury induced by unilateral ureteral obstruction. Am J Pathol 169: 1107-1117, 2006.
10. Kamijo-Ikemori A, Sugaya T, Sekizuka A, Hirata K, Kimura K. Amelioration of diabetic tubulointerstitial damage in liver-type fatty acidbinding protein transgenic mice. Nephrol Dial Transplant 24: 788-800, 2009.
11. Kawarazaki W, Nagase M, Yoshida S, Takeuchi M, Ishizawa K, Ayuzawa N, Ueda K, Fujita T. Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation. J Am Soc Nephrol 23: 997-1007, 2012.
12. KDIGO. 2012 Clinical practice guideline for the evaluation, and management of chronic kidney disease. Kidney Int 3: S1-150, 2013.
13. Kusunoki H, Taniyama Y, Rakugi H, Morishita R. Cardiac and renal protective effects of irbesartan via peroxisome proliferator-activated receptor γ-hepatocyte growth factor pathway independent of angiotensin II Type 1a receptor blockade in mouse model of salt-sensitive hypertension. J Am Heart Assoc 2: e000103, 2013.
14. Lara LS, McCormack M, Semprum-Prieto LC, Shenouda S, Majid DS, Kobori H, Navar LG, Prieto MC. AT1 receptor-mediated augmentation of angiotensinogen, oxidative stress, and inflammation in ANG II-salt hypertension. Am J Physiol Renal Physiol 302: F85-F94, 2012.
15. Lopez-Parra V, Mallavia B, Lopez-Franco O, Ortiz-Muñoz G, Oguiza A, Recio C, Blanco J, Nimmerjahn F, Egido J, Gomez-Guerrero C. Fcγ receptor deficiency attenuates diabetic nephropathy. J Am Soc Nephrol 23: 1518-15127, 2012.
16. Maatman RG, van de Westerlo EM, van Kuppevelt TH, Veerkamp JH. Molecular identification of the liver- and the heart-type fatty acidbinding proteins in human and rat kidney. Use of the reverse transcriptase polymerase chain reaction. Biochem J 288: 285-290, 1992.
17. Matsui K, Kamijo-Ikemori A, Sugaya T, Yasuda T, Kimura K. Renal liver-type fatty acid binding protein (L-FABP) attenuates acute kidney injury in aristolochic acid nephrotoxicity. Am J Pathol 178: 1021-1032, 2011.
18. Nakamura T, Fujiwara N, Kawagoe Y, Sugaya T, Ueda Y, Koide H. Effects of telmisartan and enalapril J on renoprotection in patients with mild to moderate chronic kidney disease. Eur J Clin Invest 40: 790-796, 2010.
19. Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Node K. Renoprotective effect of telmisartan in patients with chronic kidney disease. Clin Exp Hypertens 30: 662-672, 2008.
20. Nakamura T, Sato E, Amaha M, Kawagoe Y, Maeda S, Yamagishi S. Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria. J Renin Angiotensin Aldosterone Syst 13: 122-127, 2012.
21. Osaki K, Suzuki Y, Sugaya T, Tanifuji C, Nishiyama A, Horikoshi S, Tomino Y. Amelioration of angiotensin II-induced salt-sensitive hypertension by liver-type fatty acid-binding protein in proximal tubules. Hypertension 62: 712-718, 2013.
22. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; Investigators ALTITUDE. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 367: 2204-2213, 2012.
23. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G. Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941-1951, 2004.
24. Sato K, Kihara M, Hashimoto T, Matsushita K, Koide Y, Tamura K, et al. Alterations in renal endothelial nitric oxide synthase expression by salt diet in angiotensin type-1a receptor gene knockout mice. J Am Soc Nephrol 15: 1756-1763.2004.
25. Smathers RL, Galligan JJ, Shearn CT, Fritz KS, Mercer K, Ronis M, Orlicky DJ, Davidson NO, Petersen DR. Susceptibility of L-FABP-/- mice to oxidative stress in early-stage alcoholic liver. J Lipid Res 54: 1335-1345, 2013.
26. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med 158 825-830, 2013.
27. Sugaya T, Nishimatsu S, Tanimoto K, Takimoto E, Yamagishi T, Imamura K, Goto S, Imaizumi K, Hisada Y, Otsuka A. Angiotensin II type 1a receptor-deficient mice with hypotension and hyperreninemia. J Biol Chem 270: 18719-18722, 1995.
28. Tanifuji C, Suzuki Y, Geot WM, Horikoshi S, Sugaya T, Ruiz-Ortega M, Egido J, Tomino Y. Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells. Antioxid Redox Signal 7: 1261-1268, 2005.
29. Wang G, Gong Y, Anderson J, Sun D, Minuk G, Roberts MS, Burczynski FJ. Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells. Hepatology 42: 871-879, 2005.
30. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, Kimura K, Fujita T, Kinukawa T, Taniguchi H, Nakamura K, Goto M, Shinozaki N, Ohshima S, Sugaya T. Renal L-type fatty acid- binding protein in acute ischemic injury. J Am Soc Nephrol 18: 2894-2902, 2007.
31. Yan J, Gong Y, She YM, Wang G, Roberts MS, Burczynski FJ. Molecular mechanism of recombinant liver fatty acid binding protein's antioxidant activity. J Lipid Res 50: 2445-2454, 2009.
32. Yokoyama T, Kamijo-Ikemori A, Sugaya T, Hoshino S, Yasuda T, Kimura K Urinary. excretion of liver type fatty acid binding protein accurately reflects the degree of tubulointerstitial damage. Am J Pathol 174: 2096-2106, 2009.
33. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559, 2008.